The Promise of Anti-ErbB3 Monoclonals as New Cancer Therapeutics

Oncotarget - United States
doi 10.18632/oncotarget.550
Full Text
Abstract

Available in full text

Categories
Oncology
Date
Authors
Publisher

Impact Journals, LLC

Related search

Anti-Caveolin-1 Antibodies as Anti-Prostate Cancer Therapeutics

Hybridoma
2012English

An Evaluation of Minor Groove Binders as Anti-Lung Cancer Therapeutics

Bioorganic and Medicinal Chemistry Letters
Organic ChemistryMolecular MedicineMolecular BiologyBiochemistryClinical BiochemistryPharmaceutical ScienceDrug Discovery
2016English

Estrogen-Related Receptor Alpha (ERRa)-Coactivator Interactions as Targets for Discovery of New Anti-Breast Cancer Therapeutics

2006English

Targeting ErbB3: The New RTK(id) on the Prostate Cancer Block

Immunology, Endocrine and Metabolic Agents in Medicinal Chemistry
ImmunologyPharmacologyEndocrinologyAllergyMetabolismDiabetes
2011English

Driving Cancer Through ErbB3

Science-Business eXchange
2013English

Rapalogs and mTOR Inhibitors as Anti-Aging Therapeutics

Journal of Clinical Investigation
Medicine
2013English

ErbB Activation Signatures as Potential Biomarkers for Anti-ErbB3 Treatment in HNSCC

PLoS ONE
Multidisciplinary
2017English

Anti-Transcription Factor RNA Aptamers as Potential Therapeutics

Nucleic Acid Therapeutics
BiochemistryMolecular MedicineDrug DiscoveryGeneticsMolecular Biology
2016English

Histone Deacetylase Inhibitors as Cancer Therapeutics

Annals of Translational Medicine
Medicine
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy